Efficacy of nebulized therapy of bronchial asthma exacerbation with budesonide suspension
https://doi.org/10.18093/0869-0189-2008-0-2-25-32
Abstract
The aim of this trial was to evaluate efficacy of budesonide suspension for treatment of asthma exacerbations in comparison with systemic corticosteroids (SCS) with regards to clinical and functional changes and also to inflammatory activity in induced sputum (IS) and exhaled breath condensate (EBC). The trial involved 56 inpatients, mean age, 49.1 ± 14.3 years, with moderate and severe asthma exacerbation. The patients were divided into 2 groups: the 1st group (26 patients) received nebulized budesonide suspension (Pulmicort Respules, AstraZeneca) 2.0 mg b.i.d., the 2nd group (30 patients) were treated with oral prednisolone 30 mg daily with gradual reduction of the dose followed by withdrawal the drug. Moreover, all the patients received nebulized bronchodilators, oxygen supplementation if needed, expectorants, antibiotics, and medications for co-morbidities. Effectiveness of therapy for asthma exacerbation was evaluated with reduction in asthma attacks and additional use of short-acting β2 -agonists, improvement in daily physical activity and peak expiratory flow rate (PEFR). Spirometry with assessment of bronchodilator response, IS cell count, and measurement of NO metabolites in EBC were performed before and after treatment. In all patients, the treatment resulted in significant improvement in clinical and functional parameters with no difference between the groups. Dyspnea and wheezing improved more in budesonide group than were in prednisolone group. Good asthma control was achieved in 18 patients of the budesonide group (75 %) and in 21 patients of the prednisolone group (70 %). Partial control of asthma was achieved in 6 (25 %) and 9 (30 %) patients, respectively. The mean duration of treatment was longer in prednisolone group (9.3 ± 1.1 vs. 6.1 ± 1.0 days respectively, р < 0.001). Cytosis, eosinophil and neutrohil counts reliably decreased and macrophages number increased, EBC NO metabolite levels significantly reduced in both the groups with no difference between the groups. IS cell counts and EBC NO metabolite levels correlated to the degree of asthma control. Generally, the therapy with nebulized buidesonide was welltolerated, adverse events were more frequent in prednisolone group. Therefore, nebulized budesonide suspension was as highly clinically effective in asthma exacerbation as SCS; it could be used as the alternative drug with better safety profile.
About the Authors
L. I. Volkova
ГОУ ВПО "Сибирский государственный медицинский университет"
Russian Federation
Russian Federation
D. V. Kapitanova
МКЛПМУ "Городская больница № 3"
Russian Federation
Russian Federation
References
1. Чучалин А.Г. (ред.). Глобальная стратегия лечения и профилактики бронхиальной астмы. М.: Изд-во "Атмосфера"; 2002.
2. Rodrigo G., Rodrigo C. Corticosteroids in the emergency department therapy of acute adult asthma: an evidencebased evaluation. Chest 1999; 116: 285–295.
3. Edmonds M.L., Camargo C.A. Jr., Pollack C.V., Rowe B.H. Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: a meta-analysis. Cochrane Database of Syst. Rev. 2003; 3: CD002308.
4. Rowe B.H., Bota G.M., Fabris L. et al. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. J. A. M. A. 1999; 281: 2119–2126.
5. Matsumoto H., Ishihara K., Hasegawa T. et al. Effect of inhaled corticosteroids and short course of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest 2001; 120: 1468–1473.
6. Henzen C., Suter A., Lerch E. et al. Supression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355: 542–545.
7. Lee Wong M., Dayrit F.M., Kohli A.R. et al. Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. Chest 2002; 122: 1208–1213
8. Rodrigo G.J. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 1231–1236.
9. Belda J., Margarit G., Martinez C. et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations. Eur. Respir. J. 2007; 30: 1143–1149.
10. Gibson P.G., Saltos N., Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2001; 163: 32–36.
11. Shapiro G., Mendelson L., Kraemer M.J. et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J. Allergy Clin. Immunol. 1998; 102: 789–796.
12. Baker J.W., Mellon M., Wald J. et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999; 103: 414–421.
13. Devidayal S.S., Kumar L., Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999; 88: 835–840.
14. Scott M.B., Skoner D.P. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J. Allergy Clin. Immunol. 1999; 104: 200–209.
15. Геппе Н.А., Селиверстова Н.А., Малахов А.Б. и др. Ингаляционные кортикостероиды (пульмикорт) для небулайзерной терапии у детей. Пульмонология 2001; 2: 74–79.
16. Mitchell C.A., Alpers J.H., Morton S.M. et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma (abstract). Eur. Respir. J. 1995; 8: S490.
17. Higenbottam T.W., Britton J., Lawrence D. et al. On behalf of Pulmicort respules versus oral steroids; a prospective clinical trial in acute asthma (prospects). Adult study team. Comparison of nebulised budesonide and prednisolone in severe asthma exacerbation in adults. Biodrugs 2000; 14: 247–254.
18. Ediger D., Coscun F., Kunt Uzaslan E. et al. Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks. Tuberkuloz ve Toraks Dergisi 2006; 54: 128–136.
19. Цой А.Н., Аржакова Л.С., Архипов В.В. Фармакодинамика и клиническая эффективность ингаляционных глюкокортикостероидов у больных с обострением бронхиальной астмы. Пульмонология 2002; 3: 88–92.
20. Овчаренко С.И., Передельская О.А., Морозова Н.В., Маколкин В.И. Небулайзерная терапия бронхолитиками и суспензией пульмикорта в лечении тяжелого обострения бронхиальной астмы. Пульмонология 2003; 6: 75–83.
21. Палеев Н.Р., Черейская Н.К., Тишенина Р.С. и др. Эффективность и безопасность Бенакорта (раствор будесонида) при купировании обострения бронхиальной астмы. Пульмонология 2004; 2: 63–67.
22. Середа В.П., Свистов А.С. Эффективность небулизированного будесонида в терапии обострений бронхиальной астмы: проспективное, контролируемое исследование. Аллергология 2004; 2: 17–23.
23. Авдеев С.Н., Жестков А.В., Лещенко И.В. и др. Небулизированный будесонид при тяжелом обострении бронхиальной астмы: сравнение с системными стероидами. Мультицентровое рандомизированное контролируемое исследование. Пульмонология 2006; 4: 58–67.
24. Pin I., Gibson P.G., Kolendowiz R. et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25–29.
25. Lim S., Chung K.F. Potential role of noninvasive markers of inflammation in clinical management of asthma. Eur. Respir. Rev. 1998; 64: 1103–1107.
26. Kharitonov S.A., Barnes P.J. Exhaled markers of pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1693–1722.
27. Авдеев С.И., Анаев Э.Х., Чучалин А.Г. Применение метода индуцированной мокроты для оценки интенсивности воспаления дыхательных путей. Пульмонология 1998; 2: 81–85.
28. Jayaram L., Parameswaran K., Sears M.R., Hargreave F.E. Induced sputum cell counts: their usefulness in clinical practice. Eur. Respir. J. 2000; 16: 150–158.
29. Анаев Э.Х., Чучалин А.Г. Исследование конденсата выдыхаемого воздуха в пульмонологии (обзор зарубежной литературы). Пульмонология 2002; 1: 57–66.
30. Назаретян Э.Е., Нариманян М.З., Мартиросян Т.В., Гаспарян А.Ю. Содержание окиси азота в слюне и легочная гипертензия у больных с различной степенью тяжести бронхиальной астмы. Пульмонология 2000; 2: 23–27.
31. Wilson A.M., McFarlane L.C., Lipworth B.J. Systemic bioactivity profiles of oral prednisolone and nebulised budesonide in adult asthmatics. Chest 1998; 114: 1022–1029.
32. Wales D., Makker H., Kane J. et al. Systemic bioavailability and potency of highdose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy volunteers. Chest 1999; 115: 1278–1284.
Review
For citations:
Volkova L.I., Kapitanova D.V. Efficacy of nebulized therapy of bronchial asthma exacerbation with budesonide suspension. PULMONOLOGIYA. 2008;(2):25-32. (In Russ.) https://doi.org/10.18093/0869-0189-2008-0-2-25-32
Views:
386
Email this article 